Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?

Frontiers in Oncology

Volumn 4, Issue , 2015, Pages

  Alsalahi, Omran ^a   Dobrian, Anca D ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

adenocarcinoma; Barrett s esophagus; bile; esophageal cancer; Helicobacter pylori; NSAID; proton pump inhibitors

Indexed keywords

EID: 84969311478     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00373     Document Type: Note

References (50)

1. Spechler SJ. Barrett’s esophagus. N Engl J Med (2002) 346:836–42.10.1056/NEJMcp012118
2. Gilbert EW Luna RA Harrison VL Hunter JG. Barrett’s esophagus: a review of the literature. J Gastrointest Surg (2011) 15(5):708–18.10.1007/s11605-011-1485-y
3. Sami SS Ragunath K Iyer PG. Screening for Barrett’s esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges and future directions. Clin Gastroenterol Hepatol (2014).10.1016/j.cgh.2014.03.03624887058
4. Pohl H Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 97(2):142–6.10.1093/jnci/dji181
5. Brown LM Devesa SS Chow W-H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 100(16):1184–7.10.1093/jnci/djn21118695138
6. Wang KK Sampliner RE. Diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol (2008) 103:788–97.10.1111/j.1572-0241.2008.01835.x
7. Garnett WR. History of acid suppression: focus on the hospital setting. Pharmacotherapy (2003) 23(10P2):56S–60S.10.1592/phco.23.13.56S.3193214587958
8. Nasr AO Dillon MF Conlon S Downey P Chen G Ireland A et al. Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery (2012) 151(3):382–90.10.1016/j.surg.2011.08.02122019500
9. Huo X Juergens S Zhang X Rezaei D Yu C Strauch ED et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett’s epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 301(2):G278–86.10.1152/ajpgi.00092.2011
10. Hvid-Jensen F Pedersen L Funch-Jensen P Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther (2014) 39(9):984–91.10.1111/apt.12693
11. Ridlon JM Kang D-J Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res (2006) 47(2):241–59.10.1194/jlr.R500013-JLR20016299351
12. Kazumori H Ishihara S Kinoshita Y. Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett’s epithelium development. Gut (2009) 58(5):620–8.10.1136/gut.2008.15297519136512
13. Ghatak S Reveiller M Toia L Ivanov A Godfrey TE Peters JH. Bile acid at low ph reduces squamous differentiation and activates EGFR signaling in esophageal squamous cells in 3-D culture. J Gastrointest Surg (2013) 17(10):1723–31.10.1007/s11605-013-2287-123921815
14. Hofmann AF Mysels KJ. Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res (1992) 33(5):617–26.1619357
15. Spechler SJ. Does Barrett’s esophagus regress after surgery (or proton pump inhibitors)? Dig Dis (2014) 32(1–2):156–63.10.1159/00035718424603402
16. Zhao J Gregersen H. Relationships of CDXs and apical sodium-dependent bile acid transporter in Barrett’s esophagus. World J Gastroenterol (2013) 19(18):2736.10.3748/wjg.v19.i18.273623687410
17. Ma L Jüttner M Kullak-Ublick GA Eloranta JJ. Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-type homeobox proteins CDX1 and CDX2. Am J Physiol Gastrointest Liver Physiol (2012) 302(1):G123–33.10.1152/ajpgi.00102.201122016432
18. Westhoff B Brotze S Weston A McElhinney C Cherian R Mayo MS et al. The frequency of Barrett’s esophagus in high-risk patients with chronic GERD. Gastrointest Endosc (2005) 61(2):226–31.10.1016/S0016-5107(04)02589-115729230
19. El-Serag HB Kvapil P Hacken-Bitar J Kramer JR. Abdominal obesity and the risk of Barrett’s esophagus. Am J Gastroenterol (2005) 100(10):2151–6.10.1111/j.1572-0241.2005.00251.x16181362
20. Renehan AG Tyson M Egger M Heller RF Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 371:569–78.10.1016/S0140-6736(08)60269-X18280327
21. Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol (2011) 8:340–7.10.1038/nrgastro.2011.73
22. McQuaid KR Laine L Fennerty MB Souza R Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther (2011) 34(2):146–65.10.1111/j.1365-2036.2011.04709.x21615439
23. Nehra D Howell P Williams CP Pye JK Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut (1999) 44(5):598–602.10.1136/gut.44.5.59810205192
24. Kauer WK Peters JH DeMeester TR Feussner H Ireland AP Stein HJ et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery (1997) 122(5):874–81.10.1016/S0039-6060(97)90327-59369886
25. Castell DO Kahrilas PJ Richter JE Vakil NB Johnson DA Zuckerman S et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol (2002) 97(3):575–83.10.1111/j.1572-0241.2002.05532.x11922549
26. Spechler SJ Sharma P Traxler B Levine D Falk GW. Gastric and esophageal pH in patients with Barrett’s esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol (2006) 101(9):1964–71.10.1111/j.1572-0241.2006.00661.x16848802
27. Weber HC. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes (2014) 21(1):1–2.10.1097/MED.000000000000003124310148
28. Sharma P Morales TG Sampliner RE. Short segment Barrett’s esophagus – the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol (1998) 93(7):1033–6.10.1016/S0002-9270(98)00205-69672325
29. Loughney T Maydonovitch CL Wong RKH. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett’s esophagus. Am J Gastroenterol (1998) 93(6):916–9.10.1111/j.1572-0241.1998.00276.x9647018
30. Rudolph RE Vaughan TL Storer BE Haggitt RC Rabinovitch PS Levine DS et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 132(8):612–20.10.7326/0003-4819-132-8-200004180-0000310766679
31. Vaughan TL Dong LM Blount PL Ayub K Odze RD Sanchez CA et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol (2005) 6(12):945–52.10.1016/S1470-2045(05)70431-916321762
32. Tsibouris P Hendrickse MT Isaacs PET. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett’s oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther (2004) 20(6):645–55.10.1111/j.1365-2036.2004.02150.x15352913
33. Morris CD Armstrong GR Bigley G Green H Attwood SE. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol (2001) 96(4):990–6.10.1016/S0002-9270(00)02392-311316217
34. Kastelein F Spaander MC Biermann K Steyerberg EW Kuipers EJ Bruno MJ et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett’s esophagus. Gastroenterology (2011) 141(6):2000–8.10.1053/j.gastro.2011.08.03621878200
35. Róka R Inczefi O Kiss P Gyetvai Á Bálint L Németh I et al. The effect of combined long term aspirin and proton pump inhibitor therapy on the histological progression of Barrett’s metaplasia. Z Gastroenterol (2014) 52(05):A55.10.1055/s-0034-1376115
36. Heath EI Canto MI Piantadosi S Montgomery E Weinstein WM Herman JG et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 99(7):545–57.10.1093/jnci/djk11217405999
37. Tsibouris P Vlachou E Isaacs PET. Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett’s esophagus. World J Gastrointest Pharmacol Ther (2014) 5(1):27–39.10.4292/wjgpt.v5.i1.2724605249
38. Nguyen DM Richardson P El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology (2010) 138(7):2260–6.10.1053/j.gastro.2010.02.04520188100
39. Barnett K Bell CJ McKnight W Dicay M Sharkey KA Wallace JL. Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach. Am J Physiol Gastrointest Liver Physiol (2000) 279(6):G1292–7.11093953
40. Omer ZB Ananthakrishnan AN Nattinger KJ Cole EB Lin JJ Kong CY et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 10(7):722–7.10.1016/j.cgh.2012.02.03122426086
41. Fischbach LA Graham DY Kramer JR Rugge M Verstovsek G Parente P et al. Association between Helicobacter pylori and Barrett’s esophagus: a case-control study. Am J Gastroenterol (2014) 109(3):357–68.10.1038/ajg.2013.44324419485
42. Fujita M Nakamura Y Kasashima S Furukawa M Misaka R Nagahara H. Risk factors associated with Barrett’s epithelial dysplasia. World J Gastroenterol (2014) 20(15):4353.10.3748/wjg.v20.i15.435324764673
43. Huang JQ Zheng GF Sumanac K Irvine EJ Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology (2003) 125:1636–44.10.1053/j.gastro.2003.08.03314724815
44. Hongo M Nagasaki Y Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol (2009) 24(5):729–35.10.1111/j.1440-1746.2009.05824.x19646015
45. Okita K Amano Y Takahashi Y Mishima Y Moriyama N Ishimura N et al. Barrett’s esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol (2008) 43(12):928–34.10.1007/s00535-008-2261-y19107336
46. Goh K-L. Gastroesophageal reflux disease in Asia: a historical perspective and present challenges. J Gastroenterol Hepatol (2011) 26(s1):2–10.10.1111/j.1440-1746.2010.06534.x21199509
47. Tatsugami M Ito M Tanaka S Yoshihara M Matsui H Haruma K et al. Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev (2012) 21(11):2101–7.10.1158/1055-9965.EPI-12-073023010643
48. Chow W-H Blaser MJ Blot WJ Gammon MD Vaughan TL Risch HA et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 58(4):588–90.
49. Wu AH Crabtree JE Bernstein L Hawtin P Cockburn M Tseng CC et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer (2003) 103(6):815–21.10.1002/ijc.1088712516104
50. Devesa SS Fraumeni JF. The rising incidence of gastric cardia cancer. J Natl Cancer Inst (1999) 91(9):747–9.10.1093/jnci/91.9.747